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An engineered protein antagonist 
of K-Ras/B-Raf interaction
Monique J. Kauke1,2, Michael W. Traxlmayr  1,2, Jillian A. Parker3, Jonathan D. Kiefer4, Ryan 
Knihtila3, John McGee5, Greg Verdine5,6,7, Carla Mattos3 & K. Dane Wittrup1,2,8
Ras is at the hub of signal transduction pathways controlling cell proliferation and survival. Its 
mutants, present in about 30% of human cancers, are major drivers of oncogenesis and render tumors 
unresponsive to standard therapies. Here we report the engineering of a protein scaffold for preferential 
binding to K-Ras G12D. This is the first reported inhibitor to achieve nanomolar affinity while exhibiting 
specificity for mutant over wild type (WT) K-Ras. Crystal structures of the protein R11.1.6 in complex 
with K-Ras WT and K-Ras G12D offer insight into the structural basis for specificity, highlighting 
differences in the switch I conformation as the major defining element in the higher affinity interaction. 
R11.1.6 directly blocks interaction with Raf and reduces signaling through the Raf/MEK/ERK pathway. 
Our results support greater consideration of the state of switch I and provide a novel tool to study Ras 
biology. Most importantly, this work makes an unprecedented contribution to Ras research in inhibitor 
development strategy by revealing details of a targetable binding surface. Unlike the polar interfaces 
found for Ras/effector interactions, the K-Ras/R11.1.6 complex reveals an extensive hydrophobic 
interface that can serve as a template to advance the development of high affinity, non-covalent 
inhibitors of K-Ras oncogenic mutants.
GTPases K-Ras, H-Ras, and N-Ras comprise the most frequently mutated family of oncoproteins in human can-
cers, including three of the most lethal forms, cancers of the lung, colon, and pancreas. Known to initiate cell 
transformation and drive oncogenesis, mutant Ras proteins have been shown to promote tumor maintenance as 
well. Given the high level of incidence across a large subset of cancer types and the well-established role of Ras in 
tumor initiation, development, and progression, a large effort in Ras inhibitor development has been put forth1–3.
Despite decades of research, however, no drugs directly targeting Ras are currently available. This is primarily 
due to its disordered active site and smooth surface lacking well-defined drug-binding pockets2, 3. Mutations 
impair intrinsic Ras activity4, preventing GTP hydrolysis and resulting in constitutively active Ras capable of 
binding effector proteins including Raf5 and PI3K6. Mutational activation of Ras proteins and the subsequent 
constitutive signaling downstream drives uninhibited proliferation and promotes migration and invasion. The 
challenge of targeting Ras pharmacologically is compounded by difficulty in attaining drug specificity for mutant 
over wild type protein and the fact that each mutant is likely to function by unique mechanisms2. Here we present 
an inhibitor R11.1.6 engineered on a scaffold based on the thermostable protein Sso7d for preferential binding 
to K-Ras G12D and reveal an extensive hydrophobic interface on K-Ras that can be exploited in future inhibitor 
development.
Results
Engineering and characterization of mutant K-Ras specific protein binder R11.1.6. The 
recent success of allele-specific inhibitors for K-Ras G12C7, 8 prompted us to target the G12D mutation, pres-
ent in approximately 50% of K-Ras-driven pancreatic and colorectal cancers3. We recently showed that 
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charge-neutralized variants of the Sso7d protein from the hyperthermophilic archaeon Sulfolobus solfataricus can 
be engineered to bind targets with high affinity and specificity9. Because of its small size (7 kDa), high thermosta-
bility (Tm of 98 °C), and lack of cysteines and glycosylation sites, the Sso7d scaffold is well suited for targeting an 
intracellular protein with a cytoplasmically expressed antagonist. Using yeast surface display10, we isolated R11.1 
to preferentially bind GppNHp-loaded K-Ras G12D over WT (see Methods). Affinity maturation of R11.1 yielded 
four unique clones with varying degrees of affinity and specificity (Fig. 1a). We chose to further pursue R11.1.6, 
which binds K-Ras G12D in the GppNHp-bound state with single-digit nanomolar affinity – eight-fold greater 
than for the wild type. To our knowledge, this is the first inhibitor with such high affinity for mutant K-Ras as well 
as specificity over the wild type protein.
Intriguingly, the mutant vs. wild type specificity, but not high affinity, is lost in the GDP-bound state (Fig. 1b). 
This was observed for the parental R11.1 and the remaining affinity-matured clones as well (Extended Data Fig. 1). 
The loss of mutation-dependent binding suggests specificity is due to the conformation of GppNHp-bound K-Ras 
G12D, rather than the mutation itself. We therefore evaluated binding to K-Ras mutants G12C and G12V using 
bio-layer interferometry and found that R11.1.6 binds both mutants with an affinity comparable to K-Ras G12D 
(Fig. 1c). Given the high degree of homology between Ras isoforms K-Ras, H-Ras, and N-Ras, which share 100% 
sequence identity in the effector lobe (residues 1–86) and greater than 90% identity in the allosteric lobe (residues 
87–166)11, we expected binding of R11.1.6 to H- and N-Ras as well. Indeed, low nanomolar affinity was measured 
for both (Fig. 1d).
Co-crystal structures of R11.1.6 and K-Ras G12D and WT. To better understand their molecu-
lar interactions, we obtained co-crystal structures of R11.1.6 bound to GppNHp-loaded K-Ras G12D and to 
GppNHp-loaded K-Ras WT at resolutions of 2.20 and 2.30 Å, respectively (Fig. 2a and Extended Data Table 1). 
Only a few crystal structures of K-Ras in its active conformation have been obtained12, 13, and none in complex 
with another protein, making this a useful step in studying active K-Ras interaction with other proteins and 
in potentially developing future inhibitors via a structure-guided approach. The asymmetric unit of the K-Ras 
G12D/R11.1.6 complex contains four molecules, with distinct R11.1.6 molecules interacting at the switch I or 
switch II regions of K-Ras (Extended Data Fig. 2a). Binding at switch I appears to be an artifact of crystal contacts 
consisting of a few polar interactions and does not significantly contribute to the measured nanomolar affinity 
(Extended Data Fig. 2b). For both mutant G12D and WT structures, the K-Ras/R11.1.6 interface consists of 
switch II in a conformation that selectively exposes its hydrophobic residues, which are intercalated by a series 
of aromatic R11.1.6 residues. The surfaces of the two proteins are highly complementary, completely excluding 
Figure 1. Engineered Sso7d protein selectively binds mutant K-Ras. (a) Amino acid sequences of parental 
binder R11.1 and affinity-matured clones. The nine residues of the Sso7d binding surface are depicted in 
blue; R11.1 framework mutations are shown in red. Dissociation constants (Kd) obtained from yeast surface 
display (YSD) titrations detected using flow cytometry are given on the right. (b) YSD titrations of R11.1.6 with 
K-Ras loaded with GDP or the non-hydrolyzable GTP analog GppNHp. Error bars represent SEM of n = 3 
independent binding experiments. (c,d) Binding of R11.1.6 to immobilized GppNHp-loaded K-Ras, H-Ras, 
or N-Ras measured using bio-layer interferometry. Concentrations of R11.1.6 curves from dark to light: 1000, 
333.3, 111.1, 37, 12.3, 4.1, 1.4 nM. Kd values were calculated from steady-state values.
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solvent molecules (Fig. 2b). Interestingly, the R11.1.6 Trp25 indole side chain directly overlays with the indole 
moieties of small molecules previously identified to bind to K-Ras14 (Extended Data Fig. 3). This unique conver-
gence of a small molecule screen and directed protein evolution to the same K-Ras binding site demonstrates the 
potential of this interface for future inhibitor development.
The structures show R11.1.6 makes contact with K-Ras away from the GTP-binding active site, confirming 
that the mutant specificity is indeed due to the mutant’s conformation rather than direct contact with the mutated 
residue. Switch I of GTP-bound Ras can be found in two major interconverting conformations, state 1 and state 215. 
Recent NMR data showed that switch I in K-Ras G12D is stabilized in state 2, while WT K-Ras has a more open 
and dynamic active site, with significant population of state 1 (unpublished data). Our structural data mirror these 
results. In the G12D structure, switch I adopts a conformation resembling state 2, which places Glu37 and Glu63 
in an orientation that favors interaction with R11.1.6 residues Lys32 and Lys40 at the periphery of the interface, 
providing additional stabilizing interactions to the complex (Fig. 2c). In contrast, this R11.1.6 “lysine claw” does 
not appear to be as strong in the WT structure, in which switch I exhibits a state 1 conformation and Lys32 is 
oriented away from Glu63. These differences in interaction between Lys40 and Lys32 and switch I residues appear 
to give rise to the greater specificity of R11.1.6 for the G12D mutant. Consistently, H-Ras, which is also stabilized 
in state 215, has an affinity for R11.1.6 more similar to that obtained for K-Ras G12D than for WT K-Ras (Fig. 1). 
Presumably this change in conformation, and therefore the mutant specificity, is lost in the GDP-bound state.
R11.1.6 inhibits intrinsic K-Ras activity and interaction with B-Raf. Hydrolysis of GTP to GDP is 
required for termination of Ras signaling and is strongly dependent on GTPase-Activating Proteins (GAPs), which 
increase intrinsic hydrolysis rates by up to five orders of magnitude16. Because activating mutations such as those 
Figure 2. Switch I conformation gives rise to R11.1.6 mutant-specific binding. (a) Overlay of co-crystal 
structures of R11.1.6 with GppNHp-bound K-Ras WT and G12D. The C-terminus of R11.1.6 in both structures 
is partially disordered. (b) Binding interface between R11.1.6 (magenta) and K-Ras G12D (green) at switch II, 
highlighting the hydrophobic pocket created upon complex formation. K-Ras G12D residues are indicated in 
regular font; R11.1.6 residues are shown in italics. (c) Interactions between R11.1.6 lysine residues and K-Ras 
that give rise to greater affinity for the G12D mutant over WT. Bond distances of less than 4.0 Å are shown in 
dashed lines. A water molecule is shown as a blue sphere.
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at codon 12 inhibit GAP-mediated hydrolysis, intrinsic GTPase activity becomes the determinant of the extent of 
output signaling in Ras-driven cancers2. The interaction between Ras active site residues Tyr32 and Gln61 and a 
bridging water molecule is critical for intrinsic GTP hydrolysis17. Binding of R11.1.6 at switch II alters the position 
of these residues, preventing the active site from reaching a catalytically competent state (Fig. 3a). For both K-Ras 
G12D and WT, the intrinsic hydrolysis rate is indeed significantly impaired by the presence of R11.1.6 (Fig. 3b).
Despite pharmacologically undesirable stabilization of K-Ras in its active state, the inhibitory potential of 
R11.1.6 is redeemed by its ability to directly block Ras interaction with downstream effector Raf (Fig. 3c). The 
pool of GTP-bound Ras can potentially be sequestered by R11.1.6 and therefore unable to signal. GTP hydrol-
ysis rate constants for both K-Ras G12D and WT in the presence of R11.1.6 and a construct of Raf containing 
the two Ras binding domains (RBD and CRD) are consistent with the binder successfully competing with the 
effector protein, particularly in the case of the mutant (Fig. 3b). Crystallographic analysis further confirms the 
direct competition between Raf and R11.1.6 for Ras binding (Fig. 3c). To show this directly, we took advantage of 
yeast display technology, in which we measured binding of R11.1.6, expressed on the surface of yeast, to K-Ras 
pre-incubated with increasing concentrations of the Raf RBD (Fig. 3d). For both mutant G12D and WT K-Ras, 
the Raf RBD competed with R11.1.6 binding (Fig. 3e). As expected, nucleotide loading affected the extent of 
competition, since only GTP-bound Ras is able to bind Raf.
While clinical translation of R11.1.6 requires either an effective cytoplasmic delivery route or targeted gene ther-
apy (both significant pharmacological challenges), it is nevertheless immediately useful as a genetically encoded 
tool for studying the consequences of Ras antagonism. We examined Raf inhibition and downregulation of cell 
signaling by R11.1.6 expression. Enhanced green fluorescent protein (EGFP) fused to R11.1.6 or a scrambled control 
protein YW1 (Extended Data Fig. 4a,b), in which Tyr28 and Trp30 of the parental R11.1 are swapped to eliminate 
binding to K-Ras (Extended Data Fig. 4c), was co-transfected with mApple-tagged K-Ras G12D into HEK 293T 
cells. Co-localization on the plasma membrane was only observed between R11.1.6 and K-Ras G12D and not the 
YW1 control (Fig. 4a and Extended Data Fig. 5a). Specific binding in cells is further shown by R11.1.6’s ability to pull 
Figure 3. R11.1.6 reduces K-Ras intrinsic hydrolysis but directly competes with Raf. (a) Overlay of the co-
crystal structure of R11.1.6 with K-Ras G12D with structures of K-Ras G12D in complex with a small molecule 
(PDB ID 4DSN) and H-Ras WT (PDB ID 4G0N), showing the disruption of Y32 and Q61 by R11.1.6, with an 
open switch I conformation. (b) Intrinsic hydrolysis rate constants (khyd) of K-Ras alone or in the presence of 
R11.1.6 and/or the Ras binding domains (RBD and CRD, residues 51–196) of Raf. Error bars represent SEM 
of n = 3 independent experiments. **P < 0.01, 1-way ANOVA with Tukey post-test for analyzing all possible 
comparisons. (c) Overlay of the co-crystal structure of R11.1.6 with K-Ras G12D with the co-crystal structure 
of H-Ras WT with Raf RBD (PDB ID 4G0N). (d) Schematic representation of yeast surface display competition 
assay between R11.1.6 and Raf RBD for K-Ras binding. (e) Competition for binding of K-Ras as depicted in (d). 
Error bars represent SEM of n = 3 independent binding experiments.
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down mutant K-Ras G12D (Fig. 4b). Non-specific interactions between R11.1.6 and other intracellular proteins are 
minimal, though we show the binding of R11.1.6 to WT Ras to be comparable to mutant (Extended Data Fig. 5b).
Co-immunoprecipitation of mutant K-Ras and B-Raf is inhibited only by R11.1.6 and not the scrambled con-
trol (Fig. 4c), extending our yeast display competition findings (Fig. 3e) to the mammalian cytosol. This direct 
competition with Raf translates to inhibition of Ras-Raf signaling through the mitogen-activated protein (MAP) 
kinase cascade (Fig. 4d). The extent of signal downregulation is directly related to the concentration of R11.1.6 
in the cells (Extended Data Fig. 5c). Intriguingly, we did not observe a change in signaling through the PI3K/
AKT/mTOR pathway (Extended Data Fig. 5d). The effect of Raf inhibition on PI3K/AKT signaling has been 
shown to depend on the mutational status of Ras and Raf. Cells with mutant Ras observed either no change or 
an increase in phosphorylated AKT (pAKT) in response to Raf inhibition, while those harboring the wild type 
protein responded with a decrease in pAKT18. It is possible that R11.1.6 blockade of Ras-Raf interaction parallels 
direct Raf inhibition and results in a similar feedback response through the PI3K/AKT pathway. Because com-
pensatory mechanisms and cross-talk between pathways are strongly dependent on cell lines and Ras mutation 
status19, and since overexpression of mutant K-Ras does not incrementally increase pAKT levels in HEK 293T 
cells (Extended Data Fig. 5d), it is also likely that the lack of pAKT downregulation by R11.1.6-mediated Ras 
inhibition is related to the model system used.
Discussion
Using directed evolution of a novel protein scaffold, we have engineered R11.1.6 to specifically and tightly bind 
oncogenic K-Ras G12D. Through crystallographic analysis of complexes between R11.1.6 and both mutant G12D 
and WT K-Ras we have identified the source of specificity and gained insight into the importance of the state of 
switch I. Given its dynamic nature, the conformation of switch I in WT K-Ras is likely in a constant state of flux, 
but mutant K-Ras G12D appears to strongly favor state 2 (unpublished data). This could be exploited in the design 
of inhibitors to obtain improved mutant specificity and also reveal new pockets in the otherwise smooth protein, 
as we have shown here.
Figure 4. R11.1.6 specifically binds K-Ras G12D in cells, blocks K-Ras-B-Raf interaction, and inhibits 
signaling. (a) Co-localization of EGFP-R11.1.6 (green) with mApple-K-Ras G12D (red) in co-transfected 
HEK 293T cells. Scale bars are 10 μm. Images are representative of n = 2 biological replicates. Co-localization 
is quantified in Extended Data Figure 5a. (b) Co-immunoprecipitation of HA-tagged K-Ras G12D with 
cmyc-R11.1.6/YW1 in co-transfected HEK 293T cells, showing R11.1.6 specificity for K-Ras G12D. IP, 
immunoprecipitation; WCL, whole cell lysate. Results are representative of n = 2 biological replicates. (c) Co-
immunoprecipitation of endogenous B-Raf with HA-tagged K-Ras G12D in co-transfected HEK 293T cells, 
showing inhibition of K-Ras-B-Raf binding by R11.1.6. Results are representative of n = 3 biological replicates. 
(d) Effect of R11.1.6 on phosphorylation of endogenous MEK (pMEK) and ERK (pERK) via HA-K-Ras G12D-
induced signaling in co-transfected HEK 293T cells, showing inhibition of signaling by R11.1.6. Results are 
representative of n = 3 biological replicates. Quantification is provided in Extended Data Figure 5e. Full-length 
blots of the cropped ones shown here are given in Extended Data Figures 6, 7, and 8.
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Clinical Ras inhibition continues to be met with challenges. While a number of small molecules have been 
developed to directly block interaction of Ras with downstream effector Raf20–22, the micromolar affinity and 
small size of these compounds renders them not very potent. Peptide and protein-based Ras inhibitors have also 
been explored. Cyclic peptides23 as well as stapled SOS1 peptides24 have been shown to bind with double-digit 
nanomolar affinity, a single antibody domain was shown to exhibit preferential mutant binding25, and a mono-
body was isolated with nanomolar affinity to H- and K-Ras, but not N-Ras26. Recently, adoptive cell transfer of 
K-Ras G12D specific CD8+ T cells resulted in regression of metastatic lesions in a patient27, shedding light on the 
power of the immune system in targeting Ras-driven cancers. Despite this success, the Ras problem is far from 
solved.
R11.1.6 is unique in its extensive hydrophobic interface with K-Ras. None of the above protein molecules 
interacts primarily with switch II and those for which there is structural information reveal a polar interface 
either with switch I23–25 or elsewhere26, particularly difficult to mimic in drug development. Small molecules do 
interact at switch II making primarily hydrophobic contacts, but the interface is small and the binding weak12, 14. 
R11.1.6 explores that surface extensively. Thus, R11.1.6 can serve as a novel tool to study Ras biology, and the 
structure of the complex provides important molecular clues for how to modulate switch II to interfere with the 
Ras/Raf interaction in the development of new inhibitors.
Methods
Reagents. Detection reagents for yeast display were mouse-anti-c-MYC (clone 9E10, 13–2500), goat 
anti-chicken-AF 488 (A-11039), goat anti-mouse-AF 488 (A-11001), and Streptavidin-AF 647 (S-32357) 
from Life Technologies; chicken-anti-c-MYC (ACMYC) from Gallus Immunotech Inc.; and anti-His-AF 647 
(35370) from Qiagen. Western blot antibodies were anti-vinculin (13901S), anti-B-Raf (14814S), anti-pMEK1/2 
(Ser217/221) (9121S), anti-MEK1/2 (9122S), anti-pERK p44/42 (Thr202/Tyr204) (9101S), anti-ERK (9102S), 
anti-pAKT (Ser473) (9271S), and anti-AKT (9272S) from Cell Signaling Technologies, and anti-HA (16B12) 
from BioLegend. Blots were detected with HRP-conjugated secondaries (406401 and 405306) from BioLegend. 
GppNHp and GDP were purchased from Abcam, Jena Bioscience, and Sigma-Aldrich.
Cell culture. HEK 293T cells (ATCC) were cultured in DMEM with 10% FBS. DMEM was purchased from 
ATCC.
Subcloning and transfections. Cmyc-R11.1.6, cmyc-YW1, HA-K-Ras G12D, HA-K-Ras WT, 
EGFP-R11.1.6, EGFP-YW1, and mApple-K-Ras G12D were cloned into the gWIZ vector (Genlantis) for 
mammalian expression using In-Fusion Cloning (Clontech) according to the manufacturer’s instructions. The 
sequence for R11.1.6 was PCR amplified from the yeast display vector (pCTCON2), digested with BsaI and 
XbaI, and cloned into BsaI digested pE-SUMO-vector (LifeSensors) for bacterial protein expression. To make 
the scrambled YW1 control and R11.1.6 binding interface alanine point mutants, the QuikChange site-directed 
mutagenesis method (Agilent) was used according to the manufacturer’s instructions. Transient transfections into 
HEK 293T cells were carried out using calcium phosphate. Briefly, DNA diluted in water was added to 2 M CaCl2, 
to which 2x HBS was added dropwise. The transfection mixture was added to plated cells and incubated for 
8 hours, after which the transfection medium was replaced with complete medium. Unless indicated otherwise, 
the ratio of DNA transfected for K-Ras constructs to R11.1.6/YW1 constructs was 1:4.
Protein expression and purification. R11.1.6 and YW1 were expressed as fusion proteins consisting 
of an N-terminal hexahistidine tag, followed by small ubiquitin-like modifier (SUMO) and Sso7d, using the 
pE-SUMO-vector (LifeSensors), as previously described9. The proteins were produced in Rosetta 2 (DE3) E. 
coli cells and purified using TALON Metal Affinity Resin (Clontech). For crystallization, SUMO-R11.1.6 was 
digested with the protease Ulp1 (SUMO protease 1), resulting in cleavage of the N-terminal His6-SUMO-tag 
right before the N-terminus of R11.1.6. After overnight digestion at 22 °C, the digestion product was purified 
using TALON Metal Affinity Resin. Digested SUMO, non-digested SUMO-fusion proteins, and SUMO protease 1 
(all containing a hexahistidine tag) bound to the resin. The flow-through, only containing R11.1.6, was collected, 
buffer-exchanged to crystallization buffer (20 mM HEPES, 50 mM NaCl, 20 mM MgCl2, pH 7.5), and concen-
trated to ~22 mg/mL.
K-Ras WT, G12D, G12C, G12V, H-Ras, N-Ras (G domain, residues 1–166), the Raf RBD (residues 51–131), 
and the Raf construct of RBD and CRD (residues 51–196) were expressed in BL21(DE3) E. coli cells and 
purified as described previously28, 29. Nucleotide exchange was carried out using alkaline phosphatase beads 
(Sigma-Aldrich) to provide Ras proteins bound to a non-hydrolyzable GTP analog, guanosine 5′-[β,γ-imido]
triphosphate (GppNHp). The purified proteins were concentrated to 20–30 mg/mL and stored at −80 °C in stabi-
lization buffer (20 mM HEPES, 50 mM NaCl, 20 mM MgCl2, 1 mM DTT, 1% v/v glycerol, pH 7.5).
The K-Ras used for yeast display selections and titration experiments was expressed as a fusion protein consist-
ing of an N-terminal hexahistidine tag, followed by small ubiquitin-like modifier (SUMO) and the first 166 amino 
acids of human K-Ras isoform 4B using the pE-SUMO vector. Both K-Ras WT and K-Ras G12D were expressed 
as His6-SUMO-fusions. The proteins were produced in Rosetta 2 (DE3) E. coli cells. After expression at 30 °C for 
5 hours, cells were centrifuged and re-suspended in 40 mL HisBuffer 1 T (50 mM Tris/HCl, 300 mM NaCl, 10 mM 
imidazole, 5 mM MgCl2, pH 7.5) per 2 liters of culture volume, followed by addition of cOmplete EDTA-free 
protease inhibitor cocktail (Roche). Cells were lysed by sonication, followed by centrifugation (20,000 × g, 
15 minutes, 4 °C). The supernatant was purified using TALON Metal Affinity Resin (Clontech). After three wash-
ing steps with HisBuffer 1 T, the protein was eluted with HisBuffer 2 T (50 mM Tris/HCl, 300 mM NaCl, 150 mM 
imidazole, 5 mM MgCl2, pH 7.5). Immediately following elution from the column, DL-Dithiothreitol (DTT; 
1 mM final concentration) and cOmplete EDTA-free protease inhibitor cocktail solution (Roche) were added. 
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 5831  | DOI:10.1038/s41598-017-05889-7
The protein samples were purified on a Superdex 75 10/300 GL column (GE Healthcare), pre-equilibrated in Ras 
Phosphatase Buffer (32 mM Tris/HCl, 200 mM (NH4)2SO4, 1 mM DTT, 0.5 mM NaN3, 1 µM ZnCl2, pH 8.0). The 
purified protein was concentrated to 150–300 µM using Amicon Ultra Centrifugal Filter Units (EMD Millipore). 
After adding 0.5 µL calf intestinal alkaline phosphatase (New England Biolabs) per 100 µL of protein solution and 
GppNHp (Sigma-Aldrich) to three times the protein concentration, the K-Ras-solution was incubated at 22 °C for 
90 minutes. Subsequently, the protein samples were purified on a Superdex 75 10/300 GL column pre-equilibrated 
in Ras Storage Buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, pH 7.5). After SEC purification, 
the samples were split into two parts, of which one was biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Life 
Technologies). Protein samples were supplemented with glycerol (10% final concentration), shock frozen in liq-
uid nitrogen, and stored at −80 °C.
Sso7d selections and characterization. K-Ras binders were selected from libraries rcSso7d-11 and rcS-
so7d-189 using yeast display technology. All selections were conducted in Ras Selection Buffer (50 mM Tris/HCl, 
100 mM NaCl, 5 mM MgCl2, 1 g/L BSA, 0.1 mM DTT, 100 nM GppNHp, pH 7.4) using His6-SUMO-K-Ras-G12D 
as antigen.
Initially, bead selections were conducted using streptavidin-coated Dynabeads (Thermo Fisher) and biotiny-
lated K-Ras-G12D as described previously10. In total, two positive selections (binding to antigen-loaded beads) 
and three negative selections (incubation with unloaded beads and selection of non-bound cells) were done. 
The affinity of the bead selected libraries was improved by two rounds of affinity maturation, with each round 
consisting of error prone PCR and two rounds of magnetic bead selections. Error prone PCR was done by using 
the nucleotide analogs 8-oxo-2′-deoxyguanosine-5′-triphosphate (8-oxo-dGTP) and 2′-deoxy-p-nucleoside-5′
-triphosphate (dPTP) (2 µM each; both from TriLink BioTechnologies) as described previously10. After the 
two rounds of affinity maturation, libraries were further selected by FACS. Briefly, washed cells were incu-
bated with biotinylated SUMO-K-Ras-G12D and mouse anti-c-MYC (clone 9E10) followed by incubation with 
Streptavidin-AF 647 and goat anti-mouse IgG-AF 488. Cells were sorted on a FACS Aria IIU (BD Biosciences). 
After three rounds of FACS enrichment, individual clones were sequenced and analyzed for binding to K-Ras 
G12D and K-Ras WT, yielding the binder R11.1. Adding an excess of non-biotinylated SUMO did not block 
binding of biotinylated SUMO-K-Ras-G12D, confirming that R11.1 bound to K-Ras and not to SUMO.
In order to improve the affinity further, R11.1 was subjected to one more round of affinity maturation, consist-
ing of error prone PCR and four rounds of FACS. Sequencing of single clones yielded R11.1.1, R11.1.3, R11.1.6, 
and R11.1.8.
To obtain binding dissociation constants, individual mutants were expressed on the surface of yeast and 
tested for binding to His6-SUMO-K-Ras G12D and His6-SUMO-K-Ras WT. Titrations were performed in Ras 
Selection Buffer in the presence of either 10 µM GppNHp or 10 µM GDP. Cells were incubated with various 
concentrations of non-biotinylated His6-SUMO-K-Ras and with chicken anti-c-MYC. After washing, cells were 
stained with goat anti-chicken IgY-AF 488 and with mouse anti-penta-His-AF 647 for detecting the His-tagged 
SUMO-K-Ras proteins. Samples were analyzed on an iQue Screener (IntelliCyt).
Bio-layer interferometry (BLI). Samples were analyzed on an Octet RED96 instrument (Pall ForteBio) 
using stabilization buffer (same as above) supplemented with 0.1% BSA, 20 µL/L Tween-20, and 10 μM 
GppNHp. Biotinylated GppNHp-loaded K-Ras WT, G12D, G12C, G12V, H-Ras WT, or N-Ras WT was immo-
bilized onto streptavidin-coated BLI-tips (Pall ForteBio). Association was analyzed at various concentrations of 
SUMO-R11.1.6 or SUMO-YW1 fusion proteins (1:3 dilutions starting from 1000 nM to 1.37 nM), followed by 
measuring dissociation in buffer. Buffer baselines (Ras-loaded tips without addition of binder) were subtracted 
from the data. Dissociation constant (Kd) values were obtained from steady-state binding analysis.
Crystallization, diffraction data collection, and refinement. A 1:1 molar ratio of either K-Ras G12D 
(GppNHp) or K-Ras WT (GppNHp) and R11.1.6 was combined in stabilization buffer (same as above) and concen-
trated to ~20 mg/mL. Initial crystal hits were optimized from the Hampton Crystal Screen PEG/Ion suite (Hampton 
Research Corp). Protein crystals of the K-Ras G12D(GppNHp)/R11.1.6 complex were looped from a 2 × 2 µL hang-
ing drop over reservoir containing 0.01 M calcium chloride, 0.01 M cadmium chloride, 0.01 M cobalt(II) chloride 
hexahydrate, and 15% PEG3350. Crystals of the K-Ras WT(GppNHp)/R11.1.6 complex were looped from a similar 
reservoir condition containing 0.03 M calcium chloride, 0.03 M cadmium chloride, 0.03 M cobalt(II)chloride, and 
15% PEG3350. Crystals were cryo-protected with 10% (v/v) glycerol prior to freezing for data collection. X-Ray 
diffraction data were collected at Northeastern University on a Rigaku MicroMaxTM 007 HF generator and R-AXIS 
IV++ image plate system. Data were collected at a single wavelength (1.54 Å) and at a temperature of 100 K. Data 
were processed using HKL-3000R software package and structure refinement carried out in PHENIX and Coot. 
Both K-Ras Q61H (PDB ID 3GFT) and the solution structure of Sso7d (PDB ID 1SSO) were input as phasing 
models for molecular replacement. Data collection and refinement statistics for the co-crystal structures are shown 
in Extended Data Table 1. Ramachandran statistics for the refined K-Ras G12D/R11.1.6 and K-Ras WT/R11.1.6 
structures include 97% and 99% favored backbone angles, respectively, with no outliers.
Hydrolysis rate assay. The hydrolysis rate of both WT and K-Ras G12D was measured for the intrinsic 
reaction in the presence of γ32P-GTP, where inorganic phosphate (Pi) release is detected using a discontinuous 
radiometric assay as previously published30. Additionally, hydrolysis rate assays were conducted for K-Ras in the 
presence of 400-fold excess R11.1.6, the Ras binding domains of C-Raf (residues 51–196 containing RBD and 
CRD), or both proteins simultaneously. The hydrolysis reaction was carried out at 37 °C and measured for a total 
of 360 minutes. All experiments were conducted in triplicate, and the average concentration of Pi was normalized 
to the total GTP concentration in each reaction. DynaFit4 and Prism were used for data analysis.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 5831  | DOI:10.1038/s41598-017-05889-7
Raf competition on yeast. Experiments were conducted as yeast titrations (same as above). Briefly, yeast 
transformed with R11.1.6 were induced in SG-CAA media overnight at 20 °C. Cells were washed in stabilization 
buffer (same as above) supplemented with 0.1% BSA, 20 µl/L Tween-20, and 10 μM GppNHp or GDP. K-Ras 
G12D or WT at 10 nM was incubated with varying concentrations of the Raf RBD (residues 51–131) from 10 μM 
to 3.2 nM for approximately 30 minutes. Washed cells and chicken anti-cmyc antibody were added to K-Ras/Raf 
and incubated for approximately 3 hours, followed by incubation with goat anti-chicken-AF 488 and anti-His-AF 
647 antibodies for 20 minutes. Cells were analyzed on an iQue Screener (IntelliCyt).
Fluorescence microscopy. HEK 293T cells were plated on #1 glass cover slips (Chemglass) and tran-
siently transfected with EGFP-R11.1.6, EGFP-YW1, mApple-K-Ras G12D, or a combination thereof as indi-
cated. Approximately 24 hours after transfection, cells were fixed with 4% paraformaldehyde for 10 minutes 
at room temperature and cover slips mounted with DAPI-containing mounting medium (Vectashield, Vector 
Laboratories) and dried overnight. Images were acquired at room temperature using a GE (Applied Precision) 
DeltaVision Spectris inverted Olympus X71 microscope with a 60x objective lens, captured with a Photometrics 
CoolSNAP HQ camera. SoftWoRx software was used for image acquisition, deconvolution, and co-localization 
analysis. EGFP signal used the ex. 475/em. 528 filter set, and mApple the ex. 632/em. 685 filter set.
Co-immunoprecipitation assays. HEK 293T cells were transiently transfected in 10-cm plates with 
cmyc-R11.1.6, cmyc-YW1, HA-K-Ras G12D, or a combination thereof as indicated. Approximately 24 hours after 
transfection, cells were lysed in protease inhibitor (cOmplete EDTA-free protease inhibitor cocktail, Roche) con-
taining NP-40 lysis buffer (Abcam). Whole cell lysates were analyzed by western blot for total HA-K-Ras G12D 
and B-Raf. Cmyc-tagged R11.1.6/YW1 were pulled down with anti-cmyc beads (Thermo Scientific) and analyzed 
for co-precipitation of HA-K-Ras G12D by western blotting and co-precipitation of other intracellular proteins by 
SDS-PAGE and silver stain (Thermo Scientific). Experiment was performed in duplicate. HA-tagged K-Ras G12D 
was pulled down with anti-HA beads (Thermo Scientific) and analyzed for co-precipitation of endogenous B-Raf 
by western blotting. Experiment was performed in triplicate.
Cell signaling assay. HEK 293T cells were transiently transfected in 10-cm plates with cmyc-R11.1.6, 
cmyc-YW1, HA-K-Ras G12D, HA-K-Ras WT, or a combination thereof as indicated. Approximately 24 hours 
after transfection, cells were lysed in protease inhibitor (cOmplete EDTA-free protease inhibitor cocktail, Roche) 
containing NP-40 lysis buffer (Abcam). Whole cell lysates were analyzed by western blot for activation of MEK, 
ERK, and AKT with phosphospecific antibodies. Experiment was performed in triplicate. pMEK, MEK, pERK, 
and ERK bands were quantified using ImageJ software.
Data availability. Atomic coordinates and structure factors for the reported crystal structures have been 
deposited with the Protein Data Bank (PDB): the PDB code for K-Ras WT/R11.1.6 is 5UFE and that for K-Ras 
G12D/R11.1.6 is 5UFQ.
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